# A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer

> **NCT01240720** · PHASE1,PHASE2 · COMPLETED · sponsor: **Philogen S.p.A.** · enrollment: 65 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** 131I-F16SIP Radioimmunotherapy (RIT)

## Key facts

- **NCT ID:** NCT01240720
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2011-11
- **Final completion:** 2013-04
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2014-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01240720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01240720, "A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01240720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*